Rein Therapeutics Inc. (RNTX)
1.85
-0.06 (-3.14%)
At close: Mar 24, 2025, 3:59 PM
1.93
4.32%
After-hours: Mar 24, 2025, 04:05 PM EDT
-3.14% (1D)
| Bid | 1.7 |
| Market Cap | 40.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.88 |
| PE Ratio (ttm) | -0.64 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 2.16 |
| Volume | 8,656 |
| Avg. Volume (20D) | 76,834 |
| Open | 1.95 |
| Previous Close | 1.91 |
| Day's Range | 1.85 - 1.97 |
| 52-Week Range | 1.61 - 7.42 |
| Beta | 2.25 |
About RNTX
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 c...
Industry Medical - Pharmaceuticals
Sector Healthcare
IPO Date Jun 29, 2017
Employees 15
Stock Exchange NASDAQ
Ticker Symbol RNTX
Website http://www.reintx.com